Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.
HDFC Securities has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Alembic Pharma to report net profit at Rs. 90 crore up 0.3% year-on-year (down 23.4% quarter-on-quarter).
Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 19.6 percent Y-o-Y (down 14.1 percent Q-o-Q) to Rs. 160 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.